China · Delayed Price · Currency is CNY Guobang Pharma Statistics
Total Valuation
Guobang Pharma has a market cap or net worth of CNY 12.11 billion. The enterprise value is 10.57 billion.
| Market Cap | 12.11B |
| Enterprise Value | 10.57B |
Important Dates
The last earnings date was Saturday, October 24, 2026.
| Earnings Date | Oct 24, 2026 |
| Ex-Dividend Date | May 29, 2026 |
Share Statistics
Guobang Pharma has 770.98 million shares outstanding. The number of shares has decreased by -1.30% in one year.
| Current Share Class | 770.98M |
| Shares Outstanding | 770.98M |
| Shares Change (YoY) | -1.30% |
| Shares Change (QoQ) | -1.21% |
| Owned by Insiders (%) | 12.65% |
| Owned by Institutions (%) | 14.92% |
| Float | 313.75M |
Valuation Ratios
The trailing PE ratio is 19.49 and the forward PE ratio is 16.89.
| PE Ratio | 19.49 |
| Forward PE | 16.89 |
| PS Ratio | 1.98 |
| PB Ratio | 1.42 |
| P/TBV Ratio | 1.49 |
| P/FCF Ratio | 21.94 |
| P/OCF Ratio | 13.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.36, with an EV/FCF ratio of 19.14.
| EV / Earnings | 16.99 |
| EV / Sales | 1.72 |
| EV / EBITDA | 8.36 |
| EV / EBIT | 14.00 |
| EV / FCF | 19.14 |
Financial Position
The company has a current ratio of 2.45, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.45 |
| Quick Ratio | 1.52 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.75 |
| Debt / FCF | 1.73 |
| Interest Coverage | 34.44 |
Financial Efficiency
Return on equity (ROE) is 7.40% and return on invested capital (ROIC) is 9.50%.
| Return on Equity (ROE) | 7.40% |
| Return on Assets (ROA) | 4.32% |
| Return on Invested Capital (ROIC) | 9.50% |
| Return on Capital Employed (ROCE) | 8.65% |
| Weighted Average Cost of Capital (WACC) | 5.40% |
| Revenue Per Employee | 1.44M |
| Profits Per Employee | 146,304 |
| Employee Count | 4,251 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 2.78 |
Taxes
In the past 12 months, Guobang Pharma has paid 89.26 million in taxes.
| Income Tax | 89.26M |
| Effective Tax Rate | 12.56% |
Stock Price Statistics
The stock price has decreased by -0.70% in the last 52 weeks. The beta is 0.26, so Guobang Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | -0.70% |
| 50-Day Moving Average | 16.16 |
| 200-Day Moving Average | 16.99 |
| Relative Strength Index (RSI) | 48.47 |
| Average Volume (20 Days) | 5,105,770 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guobang Pharma had revenue of CNY 6.13 billion and earned 621.94 million in profits. Earnings per share was 0.81.
| Revenue | 6.13B |
| Gross Profit | 1.39B |
| Operating Income | 754.41M |
| Pretax Income | 710.58M |
| Net Income | 621.94M |
| EBITDA | 1.26B |
| EBIT | 754.41M |
| Earnings Per Share (EPS) | 0.81 |
Balance Sheet
The company has 2.50 billion in cash and 952.93 million in debt, with a net cash position of 1.55 billion or 2.01 per share.
| Cash & Cash Equivalents | 2.50B |
| Total Debt | 952.93M |
| Net Cash | 1.55B |
| Net Cash Per Share | 2.01 |
| Equity (Book Value) | 8.52B |
| Book Value Per Share | 11.04 |
| Working Capital | 3.68B |
Cash Flow
In the last 12 months, operating cash flow was 912.30 million and capital expenditures -360.30 million, giving a free cash flow of 552.00 million.
| Operating Cash Flow | 912.30M |
| Capital Expenditures | -360.30M |
| Depreciation & Amortization | 509.65M |
| Net Borrowing | 45.47M |
| Free Cash Flow | 552.00M |
| FCF Per Share | 0.72 |
Margins
Gross margin is 22.66%, with operating and profit margins of 12.31% and 10.15%.
| Gross Margin | 22.66% |
| Operating Margin | 12.31% |
| Pretax Margin | 11.59% |
| Profit Margin | 10.15% |
| EBITDA Margin | 20.62% |
| EBIT Margin | 12.31% |
| FCF Margin | 9.00% |
Dividends & Yields
This stock pays an annual dividend of 0.43, which amounts to a dividend yield of 2.73%.
| Dividend Per Share | 0.43 |
| Dividend Yield | 2.73% |
| Dividend Growth (YoY) | 38.65% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 56.91% |
| FCF Payout Ratio | 83.80% |
| Buyback Yield | 1.30% |
| Shareholder Yield | 4.03% |
| Earnings Yield | 5.13% |
| FCF Yield | 4.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on May 29, 2026. It was a forward split with a ratio of 1.4.
| Last Split Date | May 29, 2026 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Guobang Pharma has an Altman Z-Score of 4.61 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.61 |
| Piotroski F-Score | 6 |